Anzahl der Publikationen: 12
2017
Schütz, C.; Inselmann, S.; Saussele, Susanne; Dietz, C. T.; Müller, M. C.; Brendel, C. A.; Metzelder, S. K.; Brümmendorf, Tim H.; Waller, C.; Dengler, J.; Goebeler, M. E.; Herbst, R.; Hanzel, S.; Freunek, G.; Illmer, T.; Wang, Y.; Lange, T.; Finkernagel, F.; Hehlmann, R.; Huber, M.; Neubauer, A.; Hochhaus, A.; Guilhot, J.; Xavier Mahon, F.; Pfirrmann, Markus und Burchert, A.
(2017):
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
In: Leukemia, Bd. 31: S. 829-836
Rinaldetti, S.; Pfirrmann, M.; Manz, K.; Guilhot, J.; Panagiotidis, P.; Spiess, B.; Seifarth, W.; Fabarius, A.; Pagoni, M.; Dimou, M.; Dengler, J.; Waller, C.; Brümmendorf, T. H.; Herbst, R.; Burchert, A.; Janssen, C.; Göbeler, M. E.; Jost, P. J.; Hanzel, S.; Schafhausen, P.; Prange-Krex, G.; Illmer, T.; Janzen, V.; Klausmann, M.; Eckert, R.; Büschel, G.; Kiani, A.; Hofmann, W.-K.; Mahon, F.-X. und Saussele, S.
(2017):
Impact of ABCG2, OCT1 AND ABCB1 (MDR1) on treatment free remission in an euroski subtrial.
In: Haematologica, Bd. 102: S. 74
Pfirrmann, M.; Mahon, F.-X.; Guilhot, J.; Richter, J.; Almeida, A.; Janssen, J. J.; Mayer, J.; Koskenvesa, P.; Panayiotidis, P.; Olsson-Stromberg, U.; Berger, M. G.; Diamond, J.; Ehrencrona, H.; Kairisto, V.; Polakova, K. Machova; Müller, M. C.; Mustjoki, S.; Hochhaus, A.; Saussele, S. und Hjorth-Hansen, H.
(2017):
Chronic Myeloid Leukemia Patients Were Not Different In Molecular Relapse after Stopping Imatinib in Mr4 Whether Residual Disease Was Detected or Not - When Adjusting For Number of Control Transcripts.
In: Haematologica, Bd. 102: S. 153
2016
Pfirrmann, Markus; Baccarani, M.; Saußele, Susanne; Guilhot, J.; Cervantes, F.; Ossenkoppele, G.; Hoffmann, V. S.; Castagnetti, F.; Hasford, Joerg; Hehlmann, R. und Simonsson, B.
(2016):
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
In: Leukemia, Bd. 30, Nr. 1: S. 48-56
Hoffmann, V. S.; Baccarani, M.; Hasford, Joerg; Castagnetti, F.; Raimondo, F. di; Simonsson, B.; Indrak, K.; Sninska, Z.; Sacha, T.; Clark, R.; Bogdanovic, A.; Hellmann, A.; Griskevicius, L.; Schubert-Fritschle, Gabriele; Sertic, D.; Guilhot, J.; Lejniece, S.; Zupan, I.; Burgstaller, S.; Koskenvesa, P.; Everaus, H.; Costeas, P.; Lindörfer, Doris; Rosti, G.; Saussele, S.; Hochhaus, A.; Hehlmann, R.; Turkina, A. und Casado, L. F.
(2016):
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
In: Leukemia, Bd. 31, Nr. 3: S. 593-601
Richter, J.; Mahon, F. X.; Guilhot, J.; Hjorth-Hansen, H.; Almeida, A.; Janssen, J. J.; Mayer, J.; Porkka, K.; Panayiotidis, P.; Olsson-Strömberg, U.; Berger, M. G.; Diamond, J.; Ehrencrona, H.; Kairisto, V.; Polakova, K. Machova; Müller, M. C.; Mustjoki, S.; Hochhaus, A.; Pfirrmann, M. und Saußele, S.
(2016):
Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the euro-ski trial.
In: Haematologica, Bd. 101: S. 22-23
Burchert, A.; Inselmann, S.; Saußele, S.; Dietz, C. T.; Müller, M. C.; Eigendorff, E.; Brendel, C. A.; Metzelder, S. K.; Brümmendorf, T. H.; Waller, C.; Dengler, J.; Goebeler, M. E.; Herbst, R.; Freunek, G.; Stefan, H.; Illmer, T.; Wang, Y.; Lange, T.; Finkernagel, F.; Hehlmann, R.; Huber, M.; Neubauer, A.; Hochhaus, A.; Guilhot, J.; Mahon, F. X.; Pfirrmann, M. und Schütz, C.
(2016):
Expression of the CTLA-4 ligand CD86 (B7.2) on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in chronic myeloid leukemia.
In: Oncology Research and Treatment, Bd. 39: S. 39
Saußele, S.; Mahon, F.-X.; Guilhot, J.; Dengler, J.; Waller, C. T.; Brümmendorf, T. H.; Herbst, R.; Burchert, A.; Goebeler, M.-E.; Freunek, G.; Prümmer, O.; Jost, P. J.; Prange-Krex, G.; Illmer, T.; Janzen, V.; Schafhausen, P.; Klausmann, M.; Kiani, A.; Eckert, R.; Wit, M. de; Janssen, C.; Müller, M. C.; Hochhaus, A.; Richter, J. und Pfirrmann, M.
(2016):
Stopping tyrosine kinase inhibitors in a large cohort of European chronic myeloid leukemia (CML) patients: results of the EURO-SKI trial.
In: Oncology Research and Treatment, Bd. 39: S. 209
2015
Hoffmann, V. S.; Baccarani, M.; Hasford, Joerg; Lindörfer, Doris; Burgstaller, S.; Sertic, D.; Costeas, P.; Mayer, J.; Indrak, K.; Everaus, H.; Koskenvesa, P.; Guilhot, J.; Schubert-Fritschle, Gabriele; Castagnetti, F.; Di Raimondo, F.; Lejniece, S.; Griskevicius, L.; Thielen, N.; Sacha, T.; Hellmann, A.; Turkina, A. G.; Zaritskey, A.; Bogdanovic, A.; Sninska, Z.; Zupan, I.; Steegmann, J. L.; Simonsson, B.; Clark, R. E.; Covelli, A.; Guidi, G. und Hehlmann, R.
(2015):
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.
In: Leukemia, Bd. 29, Nr. 6: S. 1336-1343
2012
Hoffmann, Verena; Baccarani, M.; Hasford, Joerg; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus und Hehlmann, R.
(2012):
The EUTOS CML score aims to support clinical decision-making.
In: Blood, Bd. 119, Nr. 12: S. 2966-2967
2011
Hasford, Joerg; Baccarani, M.; Hoffmann, Verena; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus und Hehlmann, R.
(2011):
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
In: Blood, Bd. 118, Nr. 3: S. 686-692
2005
Hasford, Joerg; Pfirrmann, Markus; Shepherd, P.; Guilhot, J.; Hehlmann, R.; Mahon, F. X.; Kluin-Nelemans, H. C.; Ohnishi, K.; Steegmann, J. L. und Thaler, J.
(2005):
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
In: Haematologica, Bd. 90, Nr. 3: S. 335-340
Diese Liste wurde am
Sat Aug 10 19:56:21 2024 CEST
erstellt.